Endovastec(SH:688016) Sou Hu Cai Jing·2025-08-25 11:48Core Viewpoint - The company, Shanghai MicroPort CardioFlow Medtech Co., Ltd., is experiencing a decline in revenue and net profit, with a notable drop in its stock price and market valuation compared to industry averages [1][2]. Company Overview - The main business of the company includes the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2]. - Key products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2]. - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% [2]. - The gross profit margin stands at 69.61% [2]. Market Position - As of the latest data, the company's rolling price-to-earnings (PE) ratio is 32.83, while the industry average PE is 55.91, indicating a lower valuation compared to peers [1][3]. - The total market capitalization of the company is 14.692 billion yuan [1].